BRIEF-Novavax's Combo & Flu Vaccines Show Strong Immune Response, Tolerated Well in Phase 3 Trial
Reuters
Jun 11
BRIEF-Novavax's Combo & Flu Vaccines Show Strong Immune Response, Tolerated Well in Phase 3 Trial
June 11 (Reuters) - Novavax Inc NVAX.O:
NOVAVAX'S COVID-19-INFLUENZA COMBINATION AND STAND-ALONE INFLUENZA VACCINE CANDIDATES SHOWED ROBUST IMMUNE RESPONSES AND WERE WELL TOLERATED IN INITIAL COHORT OF A PHASE 3 TRIAL
NOVAVAX INC - BOTH VACCINE CANDIDATES INDUCED ROBUST IMMUNE RESPONSES
NOVAVAX INC - NO NEW SAFETY SIGNALS OBSERVED, VACCINES WELL TOLERATED
Source text: ID:nPn7t3kmXa
Further company coverage: NVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.